A Japanese company found that the antiparasitic drug ivermectin showed an “antiviral effect” against the omicron variant in a lab setting. Reuters has corrected a story in which it “misstated” that the drug was effective in a phase 3 clinical trial with human subjects. Some social media users have repeated Reuters’ reporting error but have not repeated the correction.